First human test for new 'Double-Target' antibody begins

NCT ID NCT07439263

Not yet recruiting Knowledge-focused Sponsor: Hinge Bio Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study to check the safety and side effects of a new antibody drug called HB2198 in healthy people. About 32 healthy adults will receive a single dose of the drug or a placebo. The main goal is to see how well the drug is tolerated and how it moves through the body over about two months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.